Literature DB >> 28555087

Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ.

Iwao Ojima1,2, Divya Awasthi1,2, Longfei Wei1, Krupanandan Haranahalli1.   

Abstract

This article presents an account of our research on the discovery and development of new-generation fluorine-containing antibacterial agents against drug-resistant tuberculosis, targeting FtsZ. FtsZ is an essential protein for bacterial cell division and a highly promising therapeutic target for antibacterial drug discovery. Through design, synthesis and semi-HTP screening of libraries of novel benzimidazoles, followed by SAR studies, we identified highly potent lead compounds. However, these lead compounds were found to lack sufficient metabolic and plasma stabilities. Accordingly, we have performed extensive study on the strategic incorporation of fluorine into lead compounds to improve pharmacological properties. This study has led to the development of highly efficacious fluorine-containing benzimidazoles as potential drug candidates. We have also performed computational docking analysis of these novel FtsZ inhibitors to identify their putative binding site. Based on the structural data and docking analysis, a plausible mode-of-action for this novel class of FtsZ inhibitors is proposed.

Entities:  

Keywords:  Antibacterial; Docking; Fluorine-containing benzimidazoles; FtsZ; Metabolic and plasma stability; Molecular modeling; Mycobacterium tuberculosis; Structure-activity relationship

Year:  2016        PMID: 28555087      PMCID: PMC5445929          DOI: 10.1016/j.jfluchem.2016.07.020

Source DB:  PubMed          Journal:  J Fluor Chem        ISSN: 0022-1139            Impact factor:   2.050


  43 in total

1.  Structure of Mycobacterium tuberculosis FtsZ reveals unexpected, G protein-like conformational switches.

Authors:  Adelaine K W Leung; E Lucile White; Larry J Ross; Robert C Reynolds; Joseph A DeVito; David W Borhani
Journal:  J Mol Biol       Date:  2004-09-17       Impact factor: 5.469

2.  An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.

Authors:  David J Haydon; Neil R Stokes; Rebecca Ure; Greta Galbraith; James M Bennett; David R Brown; Patrick J Baker; Vladimir V Barynin; David W Rice; Sveta E Sedelnikova; Jonathan R Heal; Joseph M Sheridan; Sachin T Aiwale; Pramod K Chauhan; Anil Srivastava; Amit Taneja; Ian Collins; Jeff Errington; Lloyd G Czaplewski
Journal:  Science       Date:  2008-09-19       Impact factor: 47.728

Review 3.  Therapeutic potential of FtsZ inhibition: a patent perspective.

Authors:  Divya Awasthi; Kunal Kumar; Iwao Ojima
Journal:  Expert Opin Ther Pat       Date:  2011-03-18       Impact factor: 6.674

Review 4.  Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ.

Authors:  Xin Li; Shutao Ma
Journal:  Eur J Med Chem       Date:  2015-03-14       Impact factor: 6.514

5.  Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents.

Authors:  Qing Huang; Fumiko Kirikae; Teruo Kirikae; Antonella Pepe; Amol Amin; Laurel Respicio; Richard A Slayden; Peter J Tonge; Iwao Ojima
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

6.  Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors.

Authors:  Bini Mathew; Shefali Srivastava; Larry J Ross; William J Suling; E Lucile White; Lisa K Woolhiser; Anne J Lenaerts; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2011-10-05       Impact factor: 3.641

Review 7.  Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).

Authors:  Jiang Wang; María Sánchez-Roselló; José Luis Aceña; Carlos del Pozo; Alexander E Sorochinsky; Santos Fustero; Vadim A Soloshonok; Hong Liu
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

8.  A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ.

Authors:  R C Reynolds; S Srivastava; L J Ross; W J Suling; E L White
Journal:  Bioorg Med Chem Lett       Date:  2004-06-21       Impact factor: 2.823

9.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

10.  2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ.

Authors:  E Lucile White; William J Suling; Larry J Ross; Lainne E Seitz; Robert C Reynolds
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

View more
  3 in total

1.  Design, synthesis and SAR study of 3rd-generation taxoids bearing 3-CH3, 3-CF3O and 3-CHF2O groups at the C2-benzoate position.

Authors:  Changwei Wang; Xin Wang; Yi Sun; Adam K Taouil; Su Yan; Galina I Botchkina; Iwao Ojima
Journal:  Bioorg Chem       Date:  2019-12-20       Impact factor: 5.275

2.  Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

Authors:  Thomas Lane; Daniel P Russo; Kimberley M Zorn; Alex M Clark; Alexandru Korotcov; Valery Tkachenko; Robert C Reynolds; Alexander L Perryman; Joel S Freundlich; Sean Ekins
Journal:  Mol Pharm       Date:  2018-04-26       Impact factor: 4.939

3.  Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.

Authors:  Jacqueto Zephyr; Desaboini Nageswara Rao; Sang V Vo; Mina Henes; Klajdi Kosovrasti; Ashley N Matthew; Adam K Hedger; Jennifer Timm; Elise T Chan; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  J Mol Biol       Date:  2022-02-17       Impact factor: 6.151

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.